logo

For the Inventor, By the Inventor

South Orange, NJ, United States of America

Joel M Friedman

This inventor holds 13 USPTO granted patents and 9 published patent applications. Top assignees: Albert Einstein College of Medicine, La Jolla Bioengineering Institute. Active years: 2010-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Joel M Friedman. Retrieved from https://idiyas.com/inventor/joel-m-friedman-y95rbisr

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 13 

% Patents Active = 92.3

Average Co-Inventor Count = 1.3

ph-index = 3

Forward Citations = 24(Granted Patents)


Location History:

  • South Orange, NJ (US) (2010 - 2018)
  • West Orange, NJ (US) (2022 - 2024)

Company Filing History:

goldMedal13 out of 514 
 
Albert Einstein College of Medicine
 patents
silverMedal1 out of 7 
 
La Jolla Bioengineering Institute
 patents
where one patent can have more than one assignee

Years Active: 2010-2026

Loading Chart...
13 patents (USPTO):Explore Patents
1. 12611431 - Approach to sustained production and delivery of nitric oxide and S-nitrosothiols (2026-04-28),
2. 12605332 - Transdermal delivery formulations (2026-04-21),
3. 12478576 - Transdermal delivery formulations (2025-11-25),
4. 12186435 - Sol-gel/hydrogel therapeutic delivery system and methods thereof (2025-01-07),
5. 12151019 - Compositions for blood storage and transfusions (2024-11-26),
6. 12059493 - Transdermal delivery formulations (2024-08-13),
7. 11786712 - Nitric oxide-releasing device (2023-10-17),
8. 11786561 - Approach to sustained production and delivery of nitric oxide and s-nitrosothiols (2023-10-17),
9. 11786456 - Transdermal delivery formulations (2023-10-17),
10. 11484493 - Transdermal delivery formulations (2022-11-01),
11. 10028918 - Nanoparticle delivery vehicle for S-nitroso-N-acetyl cysteine and uses thereof (2018-07-24),
12. 8333997 - Compositions for sustained release of nitric oxide, methods of preparing same and uses thereof (2012-12-18),
13. 7678888 - Stable oxidation resistant powdered hemoglobin, methods of preparing same, and uses thereof (2010-03-16),

Title: The Innovative Contributions of Joel M Friedman

Introduction

Joel M Friedman is a notable inventor based in South Orange, NJ (US). He has made significant contributions to the field of therapeutic delivery systems, holding a total of 13 patents. His work focuses on enhancing drug delivery methods, particularly through transdermal formulations.

Latest Patents

Friedman's latest patents include a transdermal delivery formulation designed for the delivery of a nitric oxide booster or precursor. This formulation aims to treat various diseases by enhancing the systemic level of nitric oxide in patients. Another significant patent is the sol-gel/hydrogel therapeutic delivery system, which provides a versatile platform for preparing nano and micro particles that can be loaded with small molecules. This delivery system is suitable for various drug delivery methods, including topical, transdermal, intravenous, intraperitoneal, and aerosol applications.

Career Highlights

Throughout his career, Joel M Friedman has worked with esteemed institutions such as the Albert Einstein College of Medicine and the La Jolla Bioengineering Institute. His innovative approaches have paved the way for advancements in drug delivery technologies.

Collaborations

Friedman has collaborated with notable colleagues, including Mahantesh S Navati and Parimala Nacharaju, contributing to the development of groundbreaking therapeutic solutions.

Conclusion

Joel M Friedman’s contributions to the field of therapeutic delivery systems exemplify his commitment to innovation and improving patient care. His patents and collaborations reflect a dedication to advancing medical technology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…